Seres Therapeutics, Inc.
MCRB
$7.76
-$0.20-2.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4,088.24% | 121.17% | 153.03% | 188.23% | 100.12% |
| Total Depreciation and Amortization | -14.56% | -9.73% | -9.02% | -7.30% | -3.14% |
| Total Amortization of Deferred Charges | -- | -100.00% | -73.57% | -33.10% | 24.06% |
| Total Other Non-Cash Items | 110.74% | 110.72% | -502.10% | -374.78% | -354.24% |
| Change in Net Operating Assets | 57.59% | -3.17% | 21.32% | -39.50% | -11.08% |
| Cash from Operations | 100.75% | 85.34% | 67.03% | -13.76% | -26.63% |
| Capital Expenditure | 33.68% | 73.18% | 84.69% | 91.13% | 95.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -100.00% | -88.08% | -92.45% |
| Cash from Investing | -100.03% | -100.22% | 9,921.34% | 1,729.08% | 1,244.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -141.97% | -141.97% |
| Issuance of Common Stock | -62.97% | -92.95% | -25.09% | -41.82% | 77.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 115.38% | 103.48% | -505.32% | -227.29% | -226.03% |
| Foreign Exchange rate Adjustments | -- | -- | -200.00% | -150.00% | -150.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.49% | 79.89% | 82.72% | -414.06% | -175.74% |